Difference between revisions of "Ibrutinib (PCI-32765)"

Latest revision as of 07:58, 3 January 2016

Redirect to:

@@ Line 1: / Line 1: @@
-'''In clinical trials'''.
+#REDIRECT [[Ibrutinib (Imbruvica)]]
-==General information==
-Class/mechanism: Irreversible inhibitor of Bruton's tyrosine kinase (BTK), which is an enzyme that participates in the B-cell receptor (BCR) signal cascade.  BCR signaling is believed to promote cell proliferation, adhesion, and survival in B-cell malignancies.  Inhibition of BTK interferes with the processes above and may also have a downregulating immunomodulatory effect.<ref>[http://www.pharmacyclics.com/btk_inhibitors.html Pharmacyclics BTK inhibitor website]</ref><ref>[http://www.pharmacyclics.com/clinical_trial_btk_pcyc_pci32765.html Pharmacyclics ibrutinib website]</ref>
-<br>Route: PO
-<br>Extravasation: n/a
-For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer.  Instead, for the most current information, please refer to your preferred pharmacopeias such as [http://www.thomsonhc.com/home/dispatch Micromedex], [http://online.lexi.com/ Lexicomp], [http://www.utdol.com/online/content/search.do UpToDate (courtesy of Lexicomp)], or the prescribing information.
-==Patient drug information==
-No information available.
-==References==
-<references/>